Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story ; day:15 ; month:8 ; year:2023 ; pages:1-12
Journal of endocrinological investigation ; (15.8.2023), 1-12
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40618-023-02170-9
- URN
-
urn:nbn:de:101:1-2023110310273163836989
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Faggiano, Antongiulio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
The Coordination Abilities of New Cyclic Analogs of Somatostatin
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
A case of malignant insulinoma responsive to somatostatin analogs treatment
Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
The Coordination Abilities of New Cyclic Analogs of Somatostatin
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
A case of malignant insulinoma responsive to somatostatin analogs treatment
Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor : novel applications and clinical indications for in-vivo tumor characterization
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors
The Coordination Abilities of New Cyclic Analogs of Somatostatin
Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
A case of malignant insulinoma responsive to somatostatin analogs treatment